A Two Part Study in Japanese Patients With mCRC, Consisting of an Open-label Phase I Part to Assess the Safety and Tolerability of Cediranib (AZD2171) in Combination With FOLFOX Followed by a Phase II, Randomised, Double-blind, Parallel Group Study to Assess the Efficacy of Cediranib (AZD2171) in Combination With FOLFOX.

Trial Profile

A Two Part Study in Japanese Patients With mCRC, Consisting of an Open-label Phase I Part to Assess the Safety and Tolerability of Cediranib (AZD2171) in Combination With FOLFOX Followed by a Phase II, Randomised, Double-blind, Parallel Group Study to Assess the Efficacy of Cediranib (AZD2171) in Combination With FOLFOX.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Dec 2016

At a glance

  • Drugs Cediranib (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 04 Jun 2012 Planned end date changed from 1 Mar 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 09 Aug 2011 Status changed from active, no longer recruiting to completed as reported by the Annals of Oncology.
    • 09 Aug 2011 Results published in the Annals of Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top